pharmanewsdaily

This user hasn't shared any profile information

By pharmanewsdaily On Sunday, April 11th, 2021
0 Comments

Lowering Blood Pressure Naturally with Chaksu Seeds | Cassia Absus Benefits

(adsbygoogle = window.adsbygoogle || []).push({}); Did you know that high BP management can be done without taking pills? Did you know that lowering blood pressures can be done through Chaksu Seeds? More...

By pharmanewsdaily On Sunday, February 28th, 2021
0 Comments

FDA authorizes emergency use of Janssen COVID-19 Vaccine

The US Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) for the Janssen COVID-19 Vaccine – Ad26.COV2.S manufactured by Johnson & Johnson subsidiary Janssen Biotech. It More...

By pharmanewsdaily On Wednesday, February 17th, 2021
0 Comments

Human tissue developer Humacyte to go public via $1.1bn merger with Alpha Healthcare

Humacyte, a clinical-stage biotech platform company, has agreed to merge with blank check company Alpha Healthcare Acquisition Corp. (AHAC), in a deal that values the combined firm at $1.1 billion. Based in Durham, More...

By pharmanewsdaily On Wednesday, February 17th, 2021
0 Comments

Human tissue developer Humacyte to go public via $1.1bn merger with Alpha Healthcare

Humacyte, a clinical-stage biotech platform company, has agreed to merge with blank check company Alpha Healthcare Acquisition Corp. (AHAC), in a deal that values the combined firm at $1.1 billion. Based in Durham, More...

By pharmanewsdaily On Monday, February 15th, 2021
0 Comments

G1 Therapeutics gets Cosela FDA approval to reduce chemotherapy-induced bone marrow suppression

G1 Therapeutics has bagged approval for Cosela (trilaciclib) from the US Food and Drug Administration (FDA) for reducing bone marrow suppression caused by chemotherapy. Cosela FDA approval is for its use in cutting More...

By pharmanewsdaily On Monday, February 15th, 2021
0 Comments

Targovax gets FDA fast track status for ONCOS-102 in malignant pleural mesothelioma

Targovax, a Norwegian immune-oncology company, said that its lead candidate ONCOS-102 has secured the fast track designation from the US Food and Drug Administration (FDA) for malignant pleural mesothelioma. The More...

By pharmanewsdaily On Monday, February 15th, 2021
0 Comments

G1 Therapeutics gets Cosela FDA approval to reduce chemotherapy-induced bone marrow suppression

G1 Therapeutics has bagged approval for Cosela (trilaciclib) from the US Food and Drug Administration (FDA) for reducing bone marrow suppression caused by chemotherapy. Cosela FDA approval is for its use in cutting More...

By pharmanewsdaily On Monday, February 15th, 2021
0 Comments

Targovax gets FDA fast track status for ONCOS-102 in malignant pleural mesothelioma

Targovax, a Norwegian immune-oncology company, said that its lead candidate ONCOS-102 has secured the fast track designation from the US Food and Drug Administration (FDA) for malignant pleural mesothelioma. The More...

By pharmanewsdaily On Saturday, February 13th, 2021
0 Comments

Sandoz to acquire GSK’s cephalosporin antibiotics business in $500m worth deal

Sandoz, a division of Swiss pharma giant Novartis, has agreed to acquire GSK’s cephalosporin antibiotics business in a deal worth up to $500 million. The deal gives Sandoz global rights to the Zinnat, Zinacef, More...

By pharmanewsdaily On Saturday, February 13th, 2021
0 Comments

Sandoz to acquire GSK’s cephalosporin antibiotics business in $500m worth deal

Sandoz, a division of Swiss pharma giant Novartis, has agreed to acquire GSK’s cephalosporin antibiotics business in a deal worth up to $500 million. The deal gives Sandoz global rights to the Zinnat, Zinacef, More...